Equities analysts expect Guardant Health Inc (NASDAQ:GH) to post earnings per share of ($0.34) for the current fiscal quarter, according to Zacks Investment Research. Four analysts have provided estimates for Guardant Health’s earnings, with the highest EPS estimate coming in at ($0.33) and the lowest estimate coming in at ($0.36). The firm is expected to report its next quarterly earnings results on Thursday, August 8th.
According to Zacks, analysts expect that Guardant Health will report full year earnings of ($1.48) per share for the current fiscal year, with EPS estimates ranging from ($1.51) to ($1.42). For the next year, analysts expect that the company will report earnings of ($1.02) per share, with EPS estimates ranging from ($1.41) to ($0.76). Zacks’ EPS averages are a mean average based on a survey of sell-side research firms that follow Guardant Health.
Guardant Health (NASDAQ:GH) last posted its quarterly earnings data on Thursday, May 9th. The company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.05. The firm had revenue of $36.66 million for the quarter, compared to analyst estimates of $32.12 million.
Shares of GH stock traded down $4.46 on Friday, hitting $85.05. 14,073 shares of the stock were exchanged, compared to its average volume of 714,905. The stock has a market cap of $7.63 billion and a price-to-earnings ratio of -30.38. The business has a 50-day moving average of $85.06. Guardant Health has a fifty-two week low of $27.04 and a fifty-two week high of $106.58.
In other Guardant Health news, Director Ian T. Clark sold 81,772 shares of the company’s stock in a transaction that occurred on Monday, April 15th. The stock was sold at an average price of $73.90, for a total value of $6,042,950.80. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Richard B. Lanman sold 1,690 shares of the company’s stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of $80.00, for a total value of $135,200.00. The disclosure for this sale can be found here. Insiders have sold 975,338 shares of company stock worth $66,706,026 in the last quarter.
Large investors have recently added to or reduced their stakes in the business. Mascoma Wealth Management LLC bought a new stake in Guardant Health in the first quarter valued at approximately $54,000. Legal & General Group Plc bought a new stake in Guardant Health in the fourth quarter valued at approximately $85,000. Citigroup Inc. bought a new stake in Guardant Health in the fourth quarter valued at approximately $94,000. SG Americas Securities LLC bought a new position in shares of Guardant Health during the first quarter worth approximately $108,000. Finally, Victory Capital Management Inc. bought a new position in shares of Guardant Health during the fourth quarter worth approximately $124,000. Hedge funds and other institutional investors own 69.15% of the company’s stock.
Guardant Health Company Profile
Guardant Health, Inc, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes; and GuardantOMNI, a broader gene panel, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications.
Featured Story: How to Invest in a Bull Market
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.